Find and Pitch Jounalists, Get Your Story Covered

Tags: Pharmaceuticals STAT+pharmalittle | STAT+pharmalittle drug development | Drug prices | drug pricing | Pharmaceuticals | pharmalittle | research

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Trump and tariff worries, PBM rules in New York, and more - 3 days ago STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more - 5 days ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 13 days ago STAT+: Pharmalittle: We’re reading about FDA plans to ban a cold med; Eisai Alzheimer’s drug sales, and more - 16 days ago STAT+: Pharmalittle: We’re reading about compounded Wegovy, pharmacies suing GoodRx, and more - 18 days ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 20 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 23 days ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 27 days ago STAT+: Pharmalittle: We’re reading about FDA oversight of shortages, AstraZeneca threats, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about doctors powering telehealth GLP-1 scripts, an FDA hold on a Novavax shot, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 2 months ago STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more - 3 months ago STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - 3 months ago STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more - 4 months ago STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 5 months ago STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more - 5 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 9 months ago STAT+: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies - 9 months ago STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more - 9 months ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - 9 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - 9 months ago STAT+: Pharmalittle: We’re reading about kids taking Wegovy, telehealth for abortion pills, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more - 10 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 10 months ago STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 11 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 11 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 12 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 12 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 12 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 12 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - 12 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - about 1 year ago STAT+: Pharmalittle: Pharma trade group slams European Commission proposal; U.S. lawmakers demand FDA explain its approach to shortages - about 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - about 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - about 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - about 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - about 1 year ago
2	PT Staff Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	October 2024 Product News - about 1 month ago Pharmacist Spotlight: Anjeza Fero, PharmD, RPh - 2 months ago Condition Watch, June 2024 - 5 months ago June 2024 Products Column - 5 months ago Pharmacist Spotlight: Amina Abubakar, PharmD, AAHIVP - 5 months ago Pharmacist Spotlight: Natalie Young, PharmD, BCSCP - 8 months ago Condition Watch: Migraine - 9 months ago Pharmacist Spotlight: Jake Galdo, PharmD, MBA - 12 months ago Pharmacist Spotlight: Joanna Lewis, PharmD, MBA - 12 months ago
3	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	Direct-to-Consumer Drugs: Big Pharma's Digital Health Play - 2 months ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Condition Watch, August 2024: Dermatology - 3 months ago
5	Deanna Fox, PharmD Pharmacy Times Former journalist. Now comms exec. Capital Region, New York communications	OTC Case Studies, Pain Management - 5 months ago Self-Care With Vitamins - 8 months ago Weight Loss: OTC Case Studies - about 1 year ago
6	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	OTC Guide: 28 Years Strong - 5 months ago Pharmacists Are Vital to Heart Health - 10 months ago
7	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	April 2024 - 8 months ago 2024 - 10 months ago
8	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Lifesaving Medication Plus Lifestyle Encourages Health in a “Food Plus Pharmacy” Relationship, According to Expert - 9 months ago
9	Brought to You by The Sassy Pharmacist Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Pet Peeves: January 2024 - 10 months ago Pharmacists Pet Peeves: October 2023 - about 1 year ago Pharmacists Pet Peeves: September 2023 - about 1 year ago
10	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Oncology drugmakers seek the sweet spot between efficacy and tolerability - 12 months ago

Journalists covering pharmalittle